Michal Tsur's startup Remepy raises $36 million for the development of hybrid drugs
Remepy has raised $36 million in a Series A funding round. The startup develops hybrid drugs that combine prescription medication with AI-based therapeutic applications.
Remepy, a company developing hybrid drugs, has raised $36 million in a Series A round led by O.G. Venture Partners and M Ventures, the strategic investment arm of Merck KGaA. The round included participation from existing and new investors, including NFX, Vine Ventures, TechAviv, 97212 Ventures, Qumra Capital, Fresh Fund, PsyMed Venture, Tadmor Group, and IT-Farm Corp. This latest funding brings the total capital raised by the company to $62 million.
Remepy was founded in 2022 by serial entrepreneur Dr. Michal Tsur (previously a co-founder of Sayota and Kaltura), along with Or Shoval, Eran Itam, and Professor Amir Amedi, who heads the Brain and Imaging Institute at Reichman University. The company employs approximately 60 people at its offices in Ramat Gan.
Remepy operates in a new category of medicine that combines prescription drugs with dedicated therapeutic applications based on artificial intelligence (AI). Hybrid drugs significantly improve patient outcomes by integrating drug therapy with adaptive physical, cognitive, and behavioral interventions into a unified treatment process. This approach allows for the delivery of multidisciplinary care on a large scale via a standard prescription.
Remepy recently announced a strategic collaboration with Merck KGaA (Darmstadt, Germany) to develop hybrid drugs for various indications in the field of rare tumors. Hybridopa, the company's hybrid drug program for Parkinson's disease, showed strong clinical results in Phase II, demonstrating improvements in both motor and non-motor symptoms. The company is currently preparing for global Phase III development, which is expected to begin in the fourth quarter of 2026.
"By combining biotechnology, artificial intelligence, and digital health, Remepy is redefining the way drugs are developed and the way patients use them," said Ziv Kop, managing partner at O.G. Venture Partners.
